Becton Dickinson and Co. (BDX) Stock Split and Financial Performance Review

Core Insights - Becton Dickinson and Co. (BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1] Financial Performance - On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, aimed at making shares more affordable [2][4] - BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, exceeding the consensus estimate of $2.81, with sales reaching $5.25 billion, slightly above the expected $5.15 billion [2][4] Strategic Changes - BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation [3] - The company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72, indicating a transition year according to RBC Capital Markets [3] Stock Performance - BDX's stock is currently priced at $180.62, reflecting an increase of 5.21% or $8.94, with fluctuations between a low of $170.67 and a high of $181.98 during the trading day [3] - Over the past year, BDX has reached a high of $185.02 and a low of $127.59, with a market capitalization of approximately $51.44 billion and a trading volume of 4,441,319 shares on the NYSE [3]